Nintedanib Zentiva Pharma (Nintedanib Esylate)

Nintedanib inhibits several receptor tyrosine kinases, including VEGFR, FGFR and PDGFR. By blocking these signals it reduces fibroblast activity and angiogenesis, which helps slow fibrotic lung disease progression and can limit tumor blood‑vessel formation.

The specific dose and dosing schedule are determined by the prescribing clinician based on the patient’s condition, weight, renal and hepatic function, and other medications. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Nintedanib is not recommended for use in pregnancy or while breastfeeding because safety data are limited and potential risks to the fetus or infant cannot be excluded. Women of child‑bearing potential should use effective contraception and discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nintedanib is a multi‑kinase inhibitor, whereas other antifibrotics such as pirfenidone act primarily through oxidative‑stress pathways. Nintedanib’s broader receptor blockade may offer benefit in both fibrotic lung disease and certain cancers, but the safety profile and drug‑interaction potential differ, requiring individualized assessment.

Store the product at ambient temperature, preferably below 25 °C. Keep it in the original packaging, protect it from moisture and direct sunlight, and do not use if the packaging is damaged or the tablet appears discoloured.

Nintedanib Zentiva Pharma is taken orally, usually with food to reduce gastrointestinal discomfort. The tablets should be swallowed whole with a full glass of water and not crushed, chewed, or split unless specifically instructed by a healthcare professional.

Serious risks include liver enzyme elevation, which may indicate hepatic injury, and increased bleeding, especially in patients on anticoagulants. Cardiovascular events such as arterial thrombosis have also been reported. Patients should be monitored regularly for these complications.

Nintedanib is contraindicated in patients with severe hepatic impairment, active bleeding disorders, or uncontrolled hypertension. It should also be avoided in individuals who are pregnant, breastfeeding, or have known hypersensitivity to nintedanib or any of the tablet excipients.